PD-Rx Pharmaceuticals Recalls Doxycycline Hyclate Tablets for Dissolution Failures
PD-Rx Pharmaceuticals is recalling Doxycycline Hyclate 100 mg tablets because the manufacturer reported failed dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves failed dissolution specifications without reported injuries or illnesses, fitting the criteria for a moderate severity recall.
Plain-English summary
PD-Rx Pharmaceuticals, Inc. is recalling Doxycycline Hyclate USP Tablets, 100 mg, in various bottle sizes. The recall involves 6,641 bottles distributed nationwide in the USA. The product is a prescription-only oral medication.
The recall was initiated because the manufacturer, West-Ward Pharm Corp., reported that the repackaged lots failed dissolution specifications. Dissolution is a measure of how quickly a tablet breaks down and releases the active ingredient in the body. Failed dissolution results may affect the drug's performance.
Consumers and healthcare providers should stop using the affected lots and contact their pharmacist or healthcare provider for guidance. The affected lots are identified by specific lot numbers and expiration dates listed in the recall notice.
The recalled product
- Product
- DOXYCYCLINE (DOXYCYCLINE HYCLATE)
- Brand
- DOXYCYCLINE
- Manufacturer
- PD-Rx Pharmaceuticals, Inc.
- Category
- Drug — Antibiotic
- Hazard
- Affected units
- 6,641
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: a) D17D29
- L17C73
- F18E73
- Exp. 1/31/19
- b) H17D70
- K17F66
- G18F26
- c) C18G26
- F18E36
- d) F18A85
- e) K17B44
- K17E29
- L17D93
- E17B88
- Exp. 5/31/19
- H17A52
- H17D67
- Exp. 7/31/19
- f) E17B01
- E17E83
UPCs (1)
- 0355289866954
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DOXYCYCLINE
- ModerateDoxycycline hyclate tablets recalled after stability testing failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModerateDoxycycline Capsules Recalled Due to Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- ModerateDoxycycline Capsules Recalled for Temperature Control Deviation
FDA (Drugs) · 2022-06-15
- ModeratePD-Rx Recalls Doxycycline Hyclate Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2020-06-03
- ModerateSun Pharmaceutical Recalls Doxycycline Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2020-03-25
Same manufacturer · PD-Rx Pharmaceuticals, Inc.
See all →- HighDULoxetine tablets recalled for excess nitrosamine impurity
FDA (Drugs) · 2025-01-01
- ModerateSimvastatin USP Tablets Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-05-10
- ModerateDrug Recall: Montelukast Sodium Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2023-05-10
- ModerateDrug Recall: Glimepiride 4 mg for Manufacturing Practice Deviations
FDA (Drugs) · 2023-05-10
- ModerateSimvastatin 40 mg recalled nationwide for manufacturing quality deviations
FDA (Drugs) · 2023-05-10
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17